These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 31764091)

  • 21. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
    Prince M; Lester L; Chiniwala R; Berger B
    World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serrated Polyp Yield at Colonoscopy in Patients with Positive FIT, Positive mt-sDNA, and Colonoscopy Only: Data from the New Hampshire Colonoscopy Registry.
    Anderson JC; Hisey WM; Robinson CM; Limburg PJ; Kneedler BL; Butterly LF
    Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):226-232. PubMed ID: 36409472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of Postcolonoscopy Colorectal Neoplasia by Multi-target Stool DNA.
    Ebner DW; Eckmann JD; Burger KN; Mahoney DW; Bering J; Kahn A; Rodriguez EA; Prichard DO; Wallace MB; Kane SV; Finney Rutten LJ; Gurudu SR; Kisiel JB
    Clin Transl Gastroenterol; 2021 Jun; 12(6):e00375. PubMed ID: 34140458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening.
    Imperiale TF; Porter K; Zella J; Gagrat ZD; Olson MC; Statz S; Garces J; Lavin PT; Aguilar H; Brinberg D; Berkelhammer C; Kisiel JB; Limburg PJ;
    N Engl J Med; 2024 Mar; 390(11):984-993. PubMed ID: 38477986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study.
    Wang J; Liu S; Wang H; Zheng L; Zhou C; Li G; Huang R; Wang H; Li C; Fan X; Fu X; Wang X; Guo H; Guan J; Sun Y; Song X; Li Z; Mu D; Sun J; Liu X; Qi Y; Niu F; Chen C; Wu X; Wang X; Song X; Zou H
    Clin Epigenetics; 2020 Oct; 12(1):162. PubMed ID: 33126908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
    Berger BM; Schroy PC; Dinh TA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e65-74. PubMed ID: 26792032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Patients with an Apparent False Positive Stool DNA Test: The Role of Repeat Stool DNA Testing.
    Cooper GS; Markowitz SD; Chen Z; Tuck M; Willis JE; Berger BM; Brenner DE; Li L
    Dig Dis Sci; 2018 Jun; 63(6):1449-1453. PubMed ID: 29516325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal Neoplasia Detection in Individuals With Positive Multitarget Stool DNA Tests: Data From the New Hampshire Colonoscopy Registry.
    Anderson JC; Robinson CM; Hisey WM; Edwards DK; Kneedler BL; Berger BM; Butterly LF
    J Clin Gastroenterol; 2022 May-Jun 01; 56(5):419-425. PubMed ID: 33973962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening.
    Yang C; Wu W; Yang Y; Yang X; Sun J; Zhang W; Liu K; Ying H; Jiang S; Yu X; Shi Y; Zhou Y; Zhu S; Xu Y; Ding Y; Xie L; Cai B; Xin X; Chen P; Zhao R; Wu Y
    Oncol Lett; 2020 Aug; 20(2):1193-1200. PubMed ID: 32724359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 33. Noninvasive fecal testing for colorectal cancer.
    Zou J; Xiao Z; Wu Y; Yang J; Cui N
    Clin Chim Acta; 2022 Jan; 524():123-131. PubMed ID: 34756863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia.
    Ahlquist DA; Taylor WR; Mahoney DW; Zou H; Domanico M; Thibodeau SN; Boardman LA; Berger BM; Lidgard GP
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):272-7.e1. PubMed ID: 22019796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45-49 Year-Olds: A Cross-Sectional Study.
    Imperiale TF; Kisiel JB; Itzkowitz SH; Scheu B; Duimstra EK; Statz S; Berger BM; Limburg PJ
    Cancer Prev Res (Phila); 2021 Apr; 14(4):489-496. PubMed ID: 33436397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
    Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
    J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
    [No Abstract]   [Full Text] [Related]  

  • 38. A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population.
    Sun M; Liu J; Hu H; Guo P; Shan Z; Yang H; Wang J; Xiao W; Zhou X
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2423-2432. PubMed ID: 31456088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy.
    Eckmann JD; Ebner DW; Bering J; Kahn A; Rodriguez E; Devens ME; Lowrie KL; Doering K; Then S; Burger KN; Mahoney DW; Prichard DO; Wallace MB; Gurudu SR; Finney LJ; Limburg P; Berger B; Ahlquist DA; Kisiel JB
    Am J Gastroenterol; 2020 Apr; 115(4):608-615. PubMed ID: 32068535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular stool testing as an alternative for surveillance colonoscopy: a cross-sectional cohort study.
    van Lanschot MC; Carvalho B; Coupé VM; van Engeland M; Dekker E; Meijer GA
    BMC Cancer; 2017 Feb; 17(1):116. PubMed ID: 28173852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.